HugoRCastro-MalaspinaMD

Hematology • New York, NY

Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Castro-Malaspina is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Castro-Malaspina's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 646-227-3813

Education & Training

Cayetano Heredia UniversityClass of 1971

Certifications & Licensure

NY State Medical License 1983 - 2027

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2006-2014
Super Doctor SuperDoctors.com

Clinical Trials

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2001 Jul 01
Completed
Phase 2
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403) Start of enrollment: 2007 Aug 01
Completed
Phase 3
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2006 Nov 28
Completed
Phase 2
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Feb 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

20 citations
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant.
Susan E Prockop, Aisha Hasan, Ekaterina Doubrovina, Parastoo B Dahi, Irene Rodriguez-Sanchez
The Journal of Clinical Investigation. 2023-05-15
5 citations
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem c...
Maria Sola, Valkal Bhatt, Meighan Palazzo, Kathleen E Cavalier, Sean M Devlin
Bone Marrow Transplantation. 2022-07-01
2 citations
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.
Mariam T Nawas, Jeong-Ok Lee, Jessica Flynn, Molly Maloy, Ann A Jakubowski
Bone Marrow Transplantation. 2022-07-01

Lectures

Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual MeetingDecember 3rd, 2018
Don't Miss Out!November 1st, 2018